LGALS9 and COVID-19: Small molecules and promising monoclonal antibodies under investigation in the clinical oncology area (e.g. LYT-200) that antagonize Gal-9 activity may have utility in COVID-19 (Bertino et al., 2019; Filipovic et al., 2021; Yang et al., 2021).